TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung A, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik A, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park S, Youn J, Chowdhury T, Park C, Brem H, Pardoll D, Lim M. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 2018, 7: e1466769. PMID: 30221069, PMCID: PMC6136875, DOI: 10.1080/2162402x.2018.1466769.Peer-Reviewed Original ResearchTumor-infiltrating dendritic cellsCervical lymph nodesTIGIT expressionT cellsTherapeutic targetEffector T cell functionDual checkpoint blockadePatient GBM samplesUnderlying immune mechanismsRegulatory T cellsTumor-infiltrating lymphocytesPoor survival outcomesNovel checkpoint inhibitorsT cell functionManagement of glioblastomaEffective treatment strategiesImmune therapeutic targetsLow-grade gliomasHuman GBM cellsMurine glioblastoma modelValuable therapeutic targetSuppressive TregsTIGIT pathwayCheckpoint inhibitorsInhibitory checkpoints